Navigation Links
NEURO-BIOTECH CORPORATION: Updates and latest developments
Date:11/1/2010

e automatically granted access.

Now if you review the list of licenses your company owns, you will notice that the last four licenses (13, 14, 15, 16), are what we call Neuroceuticals™. It's actually tablets to be sold in pharmacies, that will be classified and sold as "food supplements," in order to accelerate the market penetration. There will be two concentrations; one sold "over the counter," and the other with a medical prescription.

This fact is mentioned due to the ongoing actual negotiations with another Spanish party that controls networks of pharmacies across the country and in South America. Very soon, similar negotiations will open with large chains of pharmacies in the United States and Canada.

We already have on hand a first order from Egypt, and we expect to conclude and receive other sales orders in the near future. The manufacturing of these tablets do not require significant capital investments such as laboratories. Fabrication will be assigned to a pharmaceutical company, already identified, responding to all our criteria and quality standards. As for cost, it remains for us to agree on the quantities to achieve economies of scale.

Regarding our "Blood Tests," we also started preliminary discussions with chains of laboratories, in order to first, identify, evaluate and explore potential partnerships. This will avoid us having to invest in our own lab facilities in the short and medium term while ensuring the production of blood test results for health professionals to track their patients. This is exactly the same principle as a blood test ordered by your doctor to know your cholesterol levels.

We also solicited and were contacted by various insurance companies about "SymPath." This test has been the subject of numerous scientific publications and has been evaluated in over 5,000 human subjects with consistent results of 98.8% precision. With this accuracy, the results could be enough to obtain a
'/>"/>

SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
2. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
3. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
4. Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
5. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
6. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
7. China-Biotics Provides Further Updates on Qingpu New Facility
8. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
9. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
10. BioMS updates corporate strategy and adds leading healthcare investment banker
11. BioMS Medical updates University of Alberta equity position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 The human skin is ... as an important human body part. Similar to the liver, ... order to function, repair and grow. Recent reports from the ... supplements, is just as important as other life supporting organs. ... aid in skin cell reproduction, increase the appearance of skin, ...
(Date:6/18/2013)... WILMINGTON, Delaware , June 18, 2013 /PRNewswire/ ... to announce the release of the HELM biomolecular ... permissive open source MIT licence. HELM ... of a wide range of biomolecules (e.g. proteins, ... render existing small-molecule and sequence-based informatics methodologies impractical ...
(Date:6/18/2013)... The "Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research ... Analysis Services) & Application (Genomics, Proteomics & Drug Design) - Global Forecasts ... and Opportunities in North America , ... Rest of World. Browse , ... 364 Pages and an in-depth Table ...
(Date:6/18/2013)... 18, 2013 Research ... the addition of the report " DNA ... to their offering.      (Logo: ... basics of human genome variations, development of ... and small sequencers are described as well ...
Breaking Biology Technology:Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique ... ... , , ... ...
... ... , ... March 11, 2010 -- ClearTrial, the leading provider of Clinical Trial Operations (CTO) software, ... Bank and Cowen & Company at CBI,s 2010 Accounting and Reporting Congress in Philadelphia, ...
... PHILADELPHIA and LONDON , March 11 Thomson Reuters today announced it has launched the highly anticipated Academic ... to data gathering and analytics to provide a one-of-a-kind resource to the global scholarly community. , ... ... ...
Cached Biology Technology:Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage 2Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage 3ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress 2ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress 3Thomson Reuters Launches Academic Reputation Survey as Part of Global Institutional Profiles Project 2Thomson Reuters Launches Academic Reputation Survey as Part of Global Institutional Profiles Project 3
(Date:6/16/2013)... group together and move around the body called ,chase ... by scientists at UCL. , Published in Nature ... that occurs when cancer cells interact with healthy cells in ... that cancer cells recruit healthy cells and use them to ... how it could be controlled to design new therapies against ...
(Date:6/15/2013)... drug approved in Europe to treat osteoporosis has now ... cells, even in cancers that have become resistant to ... study. , The findings, presented June 15, 2013, at ... that the drug bazedoxifene packs a powerful one-two punch ... cell growth, but also flags the estrogen receptor for ...
(Date:6/14/2013)... will collaborate with researchers from Oklahoma State University, ... of Tulsa to advance understanding of how socio-ecological ... and variability in the state. , Oklahoma ... $20 million National Science Foundation Experimental Program to ... innovative research over the next five years. ...
Breaking Biology News(10 mins):'Chase and run' cell movement mechanism explains process of metastasis 2Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors 2OU researchers collaborate on $20 million NSF EPSCoR grant 2OU researchers collaborate on $20 million NSF EPSCoR grant 3
... traditional approach to pharmaceutical design uses so-called "first ... ?to initiate various cellular cascades for the desired ... all levels of research, this approach has failed ... address this major global health problem. , Enter ...
... and twig bark are helping stop the spread of ... was brought into the United States in the 1800s ... had become an out-of-control pest, crowding native plants, such ... throughout the American West. , Agricultural Research Service (ARS) ...
... New York University and Rockefeller University have discovered ... to have key roles in gene regulation, can ... MicroRNAs are a recently discovered large class of ... sites in target messenger RNA to regulate their ...
Cached Biology News:Second messenger NAADP shows fast, dose-related impact on satiety cycle 2Second messenger NAADP shows fast, dose-related impact on satiety cycle 3Beneficial Beetles Battle Pesky Saltcedar 2NYU, Rockefeller researchers find complexity of regulation by microRNA genes 2
Moue Serum 8-12 Weeks Old...
Request Info...
... • Mouse serum is collected off the clot fasted ... of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: K3EDTA ...
Recombinant Mouse Wnt-3a...
Biology Products: